-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

FDA Approves Eisai and Biogen's New Alzheimer's Therapy -- Barrons.com

Barron's · 01/06/2023 14:18
By Josh Nathan-Kazis

The Food and Drug Administration approved Biogen and Eisai's Alzheimer's disease therapy lecanemab on Friday under its accelerated approval pathway. The approval includes a warning about a side effect known as amyloid-related imaging abnormalities.

This is breaking news. Please check back for updates.

(END) Dow Jones Newswires

January 06, 2023 14:18 ET (19:18 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.